Astroglial differentiation in hNSCs treated with STAT3 inhibitors.

<p>Immunofluorescent staining is used to determine GFAP-labeled astrocytic differentiation in human neural stem cells (hNSCs) that were FHL-primed and inhibitor-treated for 4 days, and then differentiated in B27 for 9 days. (<b>A–C</b>) Representative epifluorescent microscopic images show GFAP immunoreactivity in FHL-primed hNSCs (<b>A</b>) or after treatment with Stattic (0.5 µM) (<b>B</b>) and Niclosamide (0.25 µM) (<b>C</b>). Scale bar, 10 µm. (<b>D</b>) Quantitative analyses show that 0.5 µM Stattic and 0.25 µM Niclosamide significantly decrease the percentage of GFAP⁺ cells. *<i>p</i><0.05 and ***<i>p</i><0.001 by One-way ANOVA with Tukey post-hoc tests.